 Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reportedFour out of six patients treated are still on study and PSA values are being followed up MONMOUTH JUNCTION, N.J., Jan. 12, 2023 GLOBE NEWSWIRE Advaxis, Inc. ... The post Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer appeared first on ForexTV... 